UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
____________________
FORM 8-K
____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
May 16, 2019
____________________
Pulse Biosciences, Inc.
(Exact name of registrant as specified in its charter)
____________________
|
Delaware |
|
001-37744 |
|
46-5696597 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
3957 Point Eden Way
Hayward, California 94545
(Address of principal executive offices, including zip code)
(510) 906-4600
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
|
|
☐ |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Securities registered pursuant to Section 12 (b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
||
|
Common Stock, par value $0.001 per share |
PLSE |
The Nasdaq Stock Market |
Item 5.07.Submission of Matters to a Vote of Security Holders.
On May 16, 2019, Pulse Biosciences, Inc. (the “Company”) held its Annual Meeting at the Company’s headquarters facility located at 3957 Point Eden Way, Hayward, California 94545. The stockholders of the Company voted on the following items at the Annual Meeting:
|
1. |
To elect seven directors to hold office until the Company’s 2020 annual meeting and until their successors are duly elected and qualified, subject to earlier resignation or removal; and |
|
2. |
To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019. |
The voting results for each of these proposals are detailed below:
|
1. Election of Directors |
|
Nominee |
For |
Against |
Abstained |
Broker Non-votes |
|
Kenneth A. Clark |
7,551,595 |
369,395 |
3,729 |
11,441,233 |
|
Robert W. Duggan |
7,876,470 |
46,320 |
1,929 |
11,441,233 |
|
Thomas J. Fogarty, M.D. |
7,887,276 |
31,581 |
5,862 |
11,441,233 |
|
Mitchell E. Levinson |
7,915,831 |
3,026 |
5,862 |
11,441,233 |
|
Manmeet S. Soni |
7,858,159 |
62,831 |
3,729 |
11,441,233 |
|
Darrin R. Uecker |
7,898,943 |
22,047 |
3,729 |
11,441,233 |
|
Makham Zanganeh, D.D.S |
7,879,601 |
35,256 |
9,862 |
11,441,233 |
Each director nominee was duly elected to serve until the 2020 annual meeting of stockholders and until his or her successor is duly elected and qualified.
|
2. Ratification of Appointment of Independent Registered Public Accounting Firm |
|
For |
Against |
Abstained |
Broker Non-votes |
|
19,290,028 |
354 |
75,570 |
N/A |
The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Pulse Biosciences, Inc. |
|
|
|
|
|
|
|
By: |
/s/ Brian B. Dow |
|
|
|
Brian B. Dow Chief Financial Officer, Senior Vice President, Secretary and Treasurer (Principal Financial and Principal Accounting Officer) |
Date: May 16, 2019